Rticc
Seleccione idioma:  
Buscar:
RTICC 2013
Programas RTICC
Agenda
Seguimiento cientifico
 
COORDINADOR

Coordinador: Dr. Luis Montuenga Badia
Centro: Centro para la Investigación Médica Aplicada
Dirección postal: Avda. Pío XII, 55, 31008, Pamplona
Email: lmontuenga[arroba]unav.es

Breve CV: Dr. Luis M. Montuenga got his undergraduate degree with Honors in Biology from the University of Navarra (Spain). He also has a Master of Sciences (MSc) in Neuroendocrine Cell Biology from University College London (UK). In 1984 got his Ph.D. in Biology from the University of Navarra (Spain). He spent two years as postgraduate fellow at the Royal Postgraduate Medical School in London and was Visiting Scientist at the National Cancer Institute (NIH) in Bethesda (Maryland) during three years (1995-1998). He is currently Full Professor of Cell Biology at the School of Medicine of the University of Navarra and Senior Researcher and Head of the Oncology Division of the Center for Applied Medical Research (CIMA), University of Navarra. In the past Dr. Montuenga has been the Head of the Histology and Pathology Department of the School of Medicine (1998-2007) and Vicepresident of Research of the University of Navarra (2008-2011). 

Dr. Montuenga has authored more than 120 peer-reviewed publications in Cell Biology and Oncology, has directed 18 doctoral theses and has given numerous conferences and seminars internationally. His research activity is primarily focused on lung cancer. At the Center of Applied Medical Research he co-leads, together with Dr. Ruben Pio, the Laboratory of Lung Cancer Biomarkers. The laboratory of Biomarker’s is focused on the molecular mechanisms associated with the transformation of normal lung epithelial cells into lung tumors. One of its main translational aims is to find molecular markers related to lung carcinogenesis to develop new strategies for lung cancer early detection. Other research interest of the group is to design new molecular targeted therapies that may be useful in the treatment of lung tumors.

He has served as ad hoc reviewer in a variety of national and international research evaluation agencies and has been involved in the peer review process of a large number of journals of his research field.  He is currently Associate Editor of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).

He is founding member of the European Union Early Lung Cancer (EUELC), member of the prevention Committee of the IASLC, Active member of the American Association for Cancer Research (AACR) and the European Respiratory Society as well as Spanish scientific research societies like the Asociación Española de Investigación en Cáncer (ASEICA) or the Spanish Society for Cell Biology (SEBC).

In the past editions of the RTICC network, Dr. Montuenga has been the Coordinator for Training and Mobility and now serves as Coordinator of the Respiratory Tract Tumors Program.

Introducción
Coordinador
Grupos
Work Packages
Publicaciones
Proyectos
Ensayos clínicos
Otros resultados
Agenda
Enlaces
Intranet
Noticias
Publicaciones
RD12/0036/0002
The C-terminal SH3 domain contributes to the intramolecular inhibition of Vav family proteins.
Barreira M, Fabbiano S, Couceiro JR, Torreira E, Martínez-Torrecuadrada JL, Montoya G, Llorca O, Bustelo XR
Science signaling  2014.  321.  ra35.  PMID: 24736456. 

RD12/0036/0002
Role of Src homology domain binding in signaling complexes assembled by the murid ?-herpesvirus M2 protein.
Pires de Miranda M, Lopes FB, McVey CE, Bustelo XR, Simas JP
The Journal of biological chemistry  2013.  6.  3858-70.  PMID: 23258536. 

RD12/0036/0002
Coronin1 proteins dictate rac1 intracellular dynamics and cytoskeletal output.
Ojeda V, Castro-Castro A, Bustelo XR
Molecular and cellular biology  2014.  18.  3388-406.  PMID: 24980436. 

RD12/0036/0002
GENETIC DISSECTION OF THE Vav2-Rac1 SIGNALING AXIS IN VASCULAR SMOOTH MUSCLE CELLS.
Fabbiano S, Menacho-Márquez M, Sevilla MA, Albarrán-Juárez J, Zheng Y, Offermanns S, Montero MJ, Bustelo XR
Molecular and cellular biology  2014.  PMID: 25288640. 

RD12/0036/0002
Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease.
Larive RM, Moriggi G, Menacho-Márquez M, Cañamero M, Álava Ed, Alarcón B, Dosil M, Bustelo XR
Nature communications  2014.  3881.  PMID: 24826867. 

RD12/0036/0003
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F
International journal of cancer. Journal international du cancer  2013.  1.  235-46.  PMID: 23292912. 

RD12/0036/0003
ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.
Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparís-Ogando A, de la Cruz-Morcillo MÁ, Melgar-Rojas P, García-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Giménez-Bachs JM, Salinas-Sánchez AS, Pandiella A, del Peso L, Sánchez-Prieto R
Neoplasia (New York, N.Y.)  2013.  6.  649-59.  PMID: 23730213. 

RD12/0036/0003
The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.
Rovida E, Di Maira G, Tusa I, Cannito S, Paternostro C, Navari N, Vivoli E, Deng X, Gray NS, Esparís-Ogando A, David E, Pandiella A, Dello Sbarba P, Parola M, Marra F
Gut  2014.  PMID: 25183205. 

RD12/0036/0003
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC, Esparís-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocaña A, Pandiella A
Oncogene  2014.  2.  148-56.  PMID: 23246963. 

RD12/0036/0003
Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.
Montero JC, Seoane S, Pandiella A
Cellular signalling  2013.  11.  2281-9.  PMID: 23899556. 

ISCII
ISCII
 
Ministerio de Economia y Competitividad
Descargar
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Logotipos
 
ISCII
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
|
|
|
|
 
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos
RSS